Primary analysis of KAITLIN: A phase III study of trastuzumab emtansine (T-DM1) + pertuzumab versus trastuzumab + pertuzumab + taxane, after anthracyclines as adjuvant therapy for high-risk HER2-positive early breast cancer (EBC).
Year: 2020
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Nadia Harbeck, Seock-Ah Im, Carlos H. Barrios, Herve R. Bonnefoi, Julie Gralow, Masakazu Toi, Paul Ellis, Luca Gianni, Sandra M. Swain, Young-Hyuck Im, Michelino De Laurentiis, Zbigniew Nowecki, Jigna Shah, Thomas Boulet, Haiying Liu, Harrison Macharia, Peter Trask, Chunyan Song, Eric P. Winer, Ian E. Krop
Institutions: Ludwig-Maximilians-Universität München, Seoul National University, Seoul National University Hospital, Hospital Mãe de Deus, Université de Bordeaux, Institut Bergonié, Seattle Cancer Care Alliance, Kyoto University, Guy's Hospital, Sarah Cannon Research Institute, Fondazione Michelangelo, MedStar Washington Hospital Center, NRG Oncology, Samsung Medical Center, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", The Maria Sklodowska-Curie National Research Institute of Oncology, Genentech, F. Hoffmann-La Roche AG, Harvard University, Dana-Farber Cancer Institute, Dana-Farber/Harvard Cancer Center
Language: English
Topic: HER2/EGFR in Cancer Research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
Funder: F. Hoffmann-La Roche
OpenAlex ID: W3028719789